Clinical Trial: Molecular and Structural Imaging in Atypical Alzheimer's Disease: A Longitudinal Study

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: Molecular and Structural Imaging in Atypical Alzheimer's Disease: A Longitudinal Study

Brief Summary: This is a neuroimaging study designed to learn more about amyloid and tau burden in the brain of patients with Atypical Alzheimer's Disease and how burden may change over a two-year period.

Detailed Summary:
Sponsor: Mayo Clinic

Current Primary Outcome:

  • Amount of Amyloid protein in the brain of patients with Logopenic Aphasia (LPA) or Posterior Cortical Atrophy (PCA). [ Time Frame: 5 years ]
  • Amount of Tau protein in the brain of patients with Logopenic Aphasia (LPA) or Posterior Cortical Atrophy (PCA). [ Time Frame: 5 years ]


Original Primary Outcome:

  • Amount of Amyloid protein in the brain of patients with LPA or PCA. [ Time Frame: 5 years ]
  • Amount of Tau protein in the brain of patients with LPA or PCA. [ Time Frame: 5 years ]


Current Secondary Outcome:

  • Rates of change in amyloid-PET burden over time. [ Time Frame: baseline, 2 years ]
  • Rates of change in tau-PET burden over time. [ Time Frame: baseline, 2 years ]


Original Secondary Outcome: Same as current

Information By: Mayo Clinic

Dates:
Date Received: April 7, 2016
Date Started: May 2016
Date Completion: March 2021
Last Updated: December 22, 2016
Last Verified: December 2016